Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Neal

Showing results (111-120 of 302) with videos related to

Pageof 31
Sort By:
European Urology|January 25, 2015
Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate CancerAndrew J Simpkin, Kate Tilling, Richard M Martin, et al.
Urology|August 11, 2004
Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screeningSteven E Oliver, Jeff Holly, Tim J Peters, et al.
Oncogene|April 30, 2003
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer developmentKalipso Halkidou, Vincent J Gnanapragasam, Piyush B Mehta, et al.
European Urology|January 17, 2012
Predictors of attendance for prostate-specific antigen screening tests and prostate biopsyKerry N L Avery, Chris Metcalfe, Kavita Vedhara, et al.
Biochemistry|February 1, 2013
Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancerTom Mitchell, Antonio Ramos-Montoya, Marco Di Antonio, et al.
BJU International|February 9, 2008
Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumourYasser Haba, Michael V Williams, David E Neal, et al.
Cancer Causes & Control : CCC|December 21, 2011
Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancerMari-Anne Rowlands, Jeff M P Holly, Freddie Hamdy, et al.
Cancer Causes & Control : CCC|November 11, 2016
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?Sean Harrison, Kate Tilling, Emma L Turner, et al.
Journal of Clinical Epidemiology|July 16, 2008
Development of a complex intervention improved randomization and informed consent in a randomized controlled trialJenny L Donovan, J Athene Lane, Tim J Peters, et al.
BMJ (Clinical Research Ed.)|November 17, 2007
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trialJ Athene Lane, Joanne Howson, Jenny L Donovan, et al.
Pageof 31

Showing results (111-120 of 302) with videos related to

Sort By:
Pageof 31
European Urology|January 25, 2015
Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate CancerAndrew J Simpkin, Kate Tilling, Richard M Martin, et al.
Urology|August 11, 2004
Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screeningSteven E Oliver, Jeff Holly, Tim J Peters, et al.
Oncogene|April 30, 2003
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer developmentKalipso Halkidou, Vincent J Gnanapragasam, Piyush B Mehta, et al.
European Urology|January 17, 2012
Predictors of attendance for prostate-specific antigen screening tests and prostate biopsyKerry N L Avery, Chris Metcalfe, Kavita Vedhara, et al.
Biochemistry|February 1, 2013
Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancerTom Mitchell, Antonio Ramos-Montoya, Marco Di Antonio, et al.
BJU International|February 9, 2008
Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumourYasser Haba, Michael V Williams, David E Neal, et al.
Cancer Causes & Control : CCC|December 21, 2011
Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancerMari-Anne Rowlands, Jeff M P Holly, Freddie Hamdy, et al.
Cancer Causes & Control : CCC|November 11, 2016
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?Sean Harrison, Kate Tilling, Emma L Turner, et al.
Journal of Clinical Epidemiology|July 16, 2008
Development of a complex intervention improved randomization and informed consent in a randomized controlled trialJenny L Donovan, J Athene Lane, Tim J Peters, et al.
BMJ (Clinical Research Ed.)|November 17, 2007
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trialJ Athene Lane, Joanne Howson, Jenny L Donovan, et al.
Pageof 31